SG11201509665XA - Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells - Google Patents
Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cellsInfo
- Publication number
- SG11201509665XA SG11201509665XA SG11201509665XA SG11201509665XA SG11201509665XA SG 11201509665X A SG11201509665X A SG 11201509665XA SG 11201509665X A SG11201509665X A SG 11201509665XA SG 11201509665X A SG11201509665X A SG 11201509665XA SG 11201509665X A SG11201509665X A SG 11201509665XA
- Authority
- SG
- Singapore
- Prior art keywords
- tacrolimus
- treating diseases
- neuronal cells
- protein aggregate
- diseases characterised
- Prior art date
Links
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 title 1
- 230000008021 deposition Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000002569 neuron Anatomy 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 229960001967 tacrolimus Drugs 0.000 title 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1309375.2A GB201309375D0 (en) | 2013-05-24 | 2013-05-24 | Medical methods and compounds for medical use |
| PCT/GB2014/051570 WO2014188197A1 (en) | 2013-05-24 | 2014-05-22 | Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201509665XA true SG11201509665XA (en) | 2015-12-30 |
Family
ID=48784691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509665XA SG11201509665XA (en) | 2013-05-24 | 2014-05-22 | Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells |
Country Status (8)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201600376D0 (en) * | 2016-01-08 | 2016-02-24 | Chronos Therapeutics Ltd | Novel therapeutic agents |
| MX374510B (es) * | 2017-07-04 | 2025-03-06 | Bionos Biotech S L | Uso de complejos metálicos de macroazapiridinofanos en el tratamiento de enfermedades. |
| US10752642B1 (en) | 2019-04-30 | 2020-08-25 | George Mason University | Macrocyclic lactones |
| US11666560B2 (en) | 2020-09-24 | 2023-06-06 | George Mason University | Anti-fibrotic agent |
| WO2023085363A1 (ja) * | 2021-11-12 | 2023-05-19 | 国立大学法人長崎大学 | 経皮吸収型貼付剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2279006A (en) * | 1993-06-03 | 1994-12-21 | Fujisawa Pharmaceutical Co | Treatment of amyotrophic lateral sclerosis |
| FR2810995A1 (fr) * | 2000-06-29 | 2002-01-04 | Exonhit Therapeutics Sa | Compositions et methodes pour le traitement ou la detection de pathologies neurodegeneratives |
| AR035411A1 (es) * | 2000-12-29 | 2004-05-26 | Fujisawa Pharmaceutical Co | Uso de un derivado de tacrolimus para fabricar un agente neurotrofico, composiciones y articulos de fabricacion o kits que lo comprenden, metodo para fabricar un agente que lo comprende y tejidos e injertos con una celula nerviosa tratada con este compuesto |
| GB0410101D0 (en) * | 2004-05-06 | 2004-06-09 | Leuven K U Res & Dev | Parkinson's disease |
| EP1810675A1 (en) * | 2006-01-18 | 2007-07-25 | Institut Curie | Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421 |
| WO2008122038A1 (en) * | 2007-04-02 | 2008-10-09 | President And Fellows Of Harvard College | Regulating autophagy |
| JP2012171895A (ja) * | 2011-02-18 | 2012-09-10 | Nagoya City Univ | 毛細血管拡張性失調症治療薬及びその用途 |
-
2013
- 2013-05-24 GB GBGB1309375.2A patent/GB201309375D0/en not_active Ceased
-
2014
- 2014-05-22 WO PCT/GB2014/051570 patent/WO2014188197A1/en active Application Filing
- 2014-05-22 KR KR1020157036082A patent/KR20160012184A/ko not_active Withdrawn
- 2014-05-22 CA CA2910006A patent/CA2910006A1/en not_active Abandoned
- 2014-05-22 EP EP14726740.5A patent/EP3003304A1/en not_active Withdrawn
- 2014-05-22 SG SG11201509665XA patent/SG11201509665XA/en unknown
- 2014-05-22 JP JP2016514483A patent/JP2016528171A/ja active Pending
- 2014-05-22 US US14/893,181 patent/US20160296500A1/en not_active Abandoned
-
2019
- 2019-02-15 JP JP2019025307A patent/JP2019104746A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20160296500A1 (en) | 2016-10-13 |
| JP2016528171A (ja) | 2016-09-15 |
| KR20160012184A (ko) | 2016-02-02 |
| GB201309375D0 (en) | 2013-07-10 |
| WO2014188197A1 (en) | 2014-11-27 |
| CA2910006A1 (en) | 2014-11-27 |
| EP3003304A1 (en) | 2016-04-13 |
| JP2019104746A (ja) | 2019-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267609B (en) | Beta protein inhibitors in combination with Janus kinase inhibitors for the treatment of proliferative diseases | |
| ZA201603332B (en) | Gla monotherapy for use in cancer treatment | |
| SI3542798T1 (sl) | Aceklidin za uporabo pri zdravljenju presbiopije | |
| PL3060237T3 (pl) | Zmodyfikowane białko przeprogramowujące do stosowania w leczeniu raka | |
| SI2945642T1 (sl) | Protein faktorja 1 za uporabo pri zdravljenju ali preprečevanju bolezni | |
| EP2991670B8 (en) | Sobetirome in the treatment of myelination diseases | |
| GB2516814B (en) | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer | |
| PT2976074T (pt) | Antagonistas do receptor canabinóide cb1 para utilização no tratamento de doenças associadas a anomalias dendríticas neuronais | |
| SG11201505460WA (en) | Methods for reducing aggregate levels in protein preparations by treatment with thio-heterocyclic cations | |
| EP2849785A4 (en) | METHOD FOR THE TREATMENT OF CANCER WITH NOTCH2 / 3 ANTIBODIES | |
| EP2904014A4 (en) | FOR ALTERNATIVE PATHS, SPECIFIC ANTIBODIES FOR THE TREATMENT OF HEMOLYTIC DISEASES | |
| IL232791A0 (en) | Methods of treating excess bilirubin in the blood with stanoporfin | |
| IL274047B (en) | Compounds for the treatment of blocking myelin regeneration in diseases associated with the expression of the envelope protein herv-w | |
| IL245541A0 (en) | New methods for the treatment of neurodegenerative diseases | |
| SG11201509665XA (en) | Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells | |
| IL236714A0 (en) | Anti-her2 antibodies with reduced fucosylation for use in cancer therapy | |
| IL239078A0 (en) | Protein for use in the treatment of eye diseases | |
| PT2836176T (pt) | Técnica para tratar presbiopia | |
| IL236505B (en) | Enoxacin for use in the treatment of motor neuron diseases | |
| HK40014460B (en) | Aceclidine for use in the treatment of presbyopia | |
| ZA201302565B (en) | Methods for treating hyperuricemia and related diseases | |
| HK1228736A1 (en) | Novel methods for treating neurodegenerative diseases | |
| HUE048942T2 (hu) | Antraciklin-származékok tumorbetegségek kezeléséhez |